| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Evgeny Degtyarev | Novartis | Looking back on our “Estimands in Oncology” Working Group Journey | link |
| Tobias Mütze & Stefan Englert | Novartis & J&J | Re-Thinking treatment effect measure in clinical trials with time-to-event outcomes and competing risks | link |
| Sarwar Mozumder | AstraZeneca | Outcome of Survey on Current Standards and Implementation of Covariate Adjusted and Stratified Analyses | link |
| Pedro López-Romero | Novartis | Can the Estimand Framework help improve the analysis of adverse events of special interest? | link |
Past events with contributions from the working group
Below a list of past events with contributions of the WG, with links to slidedecks and recordings (where available).
16.06.2024: PSI conference
Contribution of the working group: Invited talk
Amsterdam / Netherlands
24.11.2023: APF Workshop: Early phase clinical development – estimands, biomarkers and decision making
Contribution of the working group: Invited talk
Darmstadt / Germany
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Anja Victor | Merck KGaA | Will you learn more from your oncology dose escalation by using the estimands framework? | No presentation available |
| Stefan Englert | J&J | Estimand Framework: A New Lens for Single-Arm Early Clinical Trials in Oncology | link |
08.11.2023: Nordic lymphoma group plenary meeting
Contribution of the working group: Invited talk
Copenhagen / Denmark
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Evgeny Degtyarev | Novartis | Estimand framework – do you know the research question? | link |
16.10.2023: Seminar of the Basel Biometric Society: Estimands in Early Development (ED) across Therapeutic Areas
Contribution of the working group: Seminar
Basel / Switzerland
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Lilla di Scala | Janssen, BBS | Welcome, scene setting and “Let’s extend the conversation on estimands to Early Development” | link |
| Stefan Englert | Janssen | Why jeopardize clarity, consistency, and coherency in early phase? A plea for introducing estimand focused discussions to early development acknowledging similarities and differences as compared to late development. | link |
| Karin Meiser | Novartis | Using estimands in PoC studies for infectious diseases: what did we consider? | link |
| David Wright | Astra Zeneca | Examples of opportunities to use the estimand framework in early Phase studies | link |
| Francois Mercier | Roche | Dealing with treatment discontinuation in dose escalation Phase 1 oncology clinical trials | link |
| Rob Hemmings | Consilium Scientific | Estimands in Early Development – an external perspective | link |
| Thomas Gwise | former FDA | Optimizing Estimands with Optimus | link |
12.10.2023: FDA / Lungevity Project Significant
Contribution of the working group: Invited talk
Silver Spring / Maryland
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Kaspar Rufibach | Roche | Impact of Cross-over in the Evaluation of Overall Survival in cancer RCTs | link |
29.09.2023: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
Contribution of the working group: Panel discussion
Rockville / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Qing Xu | FDA | Contributor to panel discussion | link |
| Jonathan Siegel | Bayer | Contributor to panel discussion | link |
| Libby Floden | Clinical Outcomes Solutions | Contributor to panel discussion | link |
| Janet Wittes | Wittes LLC | Contributor to panel discussion | link |
| Hongtao Zhang | Merck | Contributor to panel discussion | link |
| Yeh-Fong Chen | FDA | Chair of panel discussion | No presentation available |
13.09.2023: EFSPI Regulatory Statistics Workshop
Contribution of the working group: Poster
Basel / Switzerland
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Sarwar Mozumder & Bjoern Bornkampp | AstraZeneca & Novartis | Conditional and Unconditional treatment effects in randomized clinical trials: Estimands , Estimation, and Interpretation | link |
05.08.2023: Joint Statistical Meetings
Contribution of the working group: Invited talk
Toronto / Canada
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Jonathan Siegel | Bayer | Estimands and Safety in Oncology Clinical Trials | link |
11.06.2023: PSI conference
Contribution of the working group: Invited session
London / UK
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Lynda Grinsted | AstraZeneca | Follow-up quantification in time to event clinical trials | link |
| Stefan Englert | J&J | Estimands in oncology early clinical developmentclinical development | link |
| Elizabeth Pilling | AstraZeneca | No presentation available | |
| Hong Tian | Beigene | No presentation available | |
| Yufei Wang | GSK | Treatment Switching Estimation based on Principal Stratification | link |
| Konstantina Skaltsa | IQVIA | How could we handle the occurrence of death when analyzing continuous endpoints? An example of PRO endpoints | link |
31.05.2023: Lifetime Data Science Conference (LIDS)
Contribution of the working group: Organizer of two sessions and invited talks
Raleigh / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Natalia Kan-Dobrosky | AbbVie | Estimands and treatment switching | link |
| Vitaly Drucker | AstraZeneca | Treatment switching adjustment in the context of non-proportional hazards | No presentation available |
| Jonathan Siegel | Bayer | Applying the estimands framework to time-to-event oncology studies: What happens when you cannot follow past an intercurrent event? | link |
| Richard Cook | University of Waterloo | Discussant | No presentation available |
| Patrick Schlömer | Bayer | Efficiency of recurrent and time-to-first event methods in the presence of terminal events – Application to chronic heart failure trials | link |
| Liwei Wang | GenMab | Logic respecting efficacy measures in the presence of prognostic or predictive biomarker subgroups | link |
| Godwin Yung | Genentech | Balancing events, not patients, maximizes power in randomized survival studies | link |
| Satrajit Roychoudhury | Pfizer | Discussant | link |
12.04.2023: Seminar of the Basel Biometrics Section
Contribution of the working group: Invited talk
Basel / Switzerland
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Rima Izem | Novartis | Welcome, scene setting and “Let us put the scientific objective first!” | link |
| Kaspar Rufibach | Roche | Stop the abuse: A plea for a more principled approach to the analysis of time-to-event endpoints with varying follow-up times and/or competing risks, with a focus on analysis of AEs. | link |
| Andrew Thomson | EMA (discussant) | Comments (no slides) | No presentation available |
| Shanti Gomatam | FDA (discussant) | Quantification of risk: ask the right questions or time to apply the estimand framework to safety | link |
29.03.2023: Duke Industry Statistics Symposium 2023
Contribution of the working group: Invited talk
USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Jonathan Siegel | Bayer | Estimands and Censoring in Oncology Time-to-Event Trials – Answering the Right Question | No presentation available |
02.12.2022: ASA New Jersey Chapter Webinar Series – Getting the question right – Applying the Estimand and Target Trial Frameworks with External Controls
Contribution of the working group: Co-organization
New Jersey / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Pallavi Mishra-Kalyani | FDA | External control arms in oncology: current use and future directions? | link |
| Xabier Garcia de Albeniz Martinez & Lisa Hampson | RTH Health Solutions & Novartis | Introduction to the ICH E9(R1) estimand and target trial emulation frameworks, and their role in the design and analysis of RWE studies | link |
| Jufen Chu | Novartis | Combining the target trial and estimand frameworks to define the causal estimand: an application using real-world data to contextualize a single-arm trial | link |
| Letizia Polito | Roche | Applying the Estimand and Target Trial frameworks to external control analyses using observational data: a case study in the solid tumor setting | link |
| Stephen Duffield | NICE | Benefits of target trial and estimand frameworks in real-world evidence of treatment effects for supporting health technology assessment | link |
21.10.2022: DIA China webinar
Contribution of the working group: Presentation
Virtual / China
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Jiajun Xu | Conditional and Marginal Treatment Effects in Clinical Trials | link |
19.10.2022: ISOQoL 2022
Contribution of the working group: Workshop
Prague / Czech Republic
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Rachael Lawrance | Patient-reported outcomes in clinical trials – what questions are we asking and how do we understand the results; how the estimand framework with sensitivity analyses can help | No presentation available |
20.09.2022: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
Contribution of the working group: Contributed topic session
Maryland / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Dalong Patrick Huang | FDA | Adjusting for covariates in randomized trials: draft guidance and some examples | link |
| Hong Tian | Beigene | Conditional and Unconditional Treatment Effects in Clinical Trials | link |
| Jonathan Siegel | Bayer | Poster on Special interest group “Estimands in oncology”, sponsored by PSI and EFSPI | link |
| Steven Sun | Contribution to panel discussion: Estimands in Oncology: | ||
| A Topical Panel Discussion | link |
14.09.2022: EFSPI Regulatory Statistics Workshop
Contribution of the working group: Poster
Basel / Switzerland
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Stefan Englert | “Poster Special interest group “Estimands in oncology”, sponsored by PSI and EFSPI” | link |
30.08.2022: 12th International Conference on Multiple Comparison Procedures
Contribution of the working group: Talk
Bremen / Germany
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Yi Liu | From Logic-respecting Efficacy Estimands to Logic-ensuring Analysis Principle in Randomized Clinical Trials with Subgroups | No presentation available |
21.08.2022: ISCB conference
Contribution of the working group: Contributed talk
Newcastle / UK
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Kaspar Rufibach | Follow-up time in clinical trials with a time-to-event endpoint: Redefining the question(s) | link |
06.08.2022: Joint Statistical Meetings
Contribution of the working group: Contributed talk
Washington / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Siyoen Kil | Insights into couterfactual estimand, with application toward personalized medicine | No presentation available |
21.07.2022: DIA annual meeting in China
Contribution of the working group: Poster
Suzhou / China
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Jiawei Wei | Poster “Special interest group “Estimands in oncology”, sponsored by PSI and EFSPI” | link |
19.06.2022: ICSA (International Chinese Statistical Association) Applied Statistics Symposium
Contribution of the working group: presentation
Gainsville Florida / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Yue Shentu | From Logic-respecting Efficacy Estimands to Logic-ensuring Analysis Principle for Time-to-event Endpoint in Randomized Clinical Trials with Subgroups | No presentation available |
12.06.2022: PSI annual conference
Contribution of the working group: Poster and invited session
Gothenburg / Sweden
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Stefan Englert (poster) | “Poster Special interest group “Estimands in oncology”, sponsored by PSI and EFSPI” | link | |
| Stefan Englert (intro talk) | Introduction to the Estimands in OncologyWorking Group | link | |
| Oliver Sailer | Duration of response and time to response into the estimand framework | link | |
| Bjoern Bornkamp | Covariate adjust with binary and time to event endpoint and how to interpret marginal effect in oncology clinical trials | link | |
| Stefan Englert (talk) | Censoring and censoring mechanisms in light of the estimand framework | link | |
| Rachael Lawrance | Estimands in Oncology Working Group PRO TaskForce | link |
26.05.2022: ASA Biopharmaceutical Section
Contribution of the working group: webinar
Virtual / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Yi Liu | From Logic-respecting Efficacy Estimands to Logic-ensuring Analysis Principle in Randomized Clinical Trials with Subgroups | No presentation available |
15.05.2022: Society for Clinical Trials
Contribution of the working group: Invited talk
San Diego / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Rachael Lawrance | The Estimand Framework from the ICH E9(R1) Statistical Principles for Clinical Trials Addendum: Current Implementation Status and Looking Forward | No presentation available | |
| Godwin Yung | Answering old questions with new tools: Application of the ICH E9 addendum in oncology | link |
26.04.2022: PSI Journal Club – Treatment Switching in Clinical Trials
Contribution of the working group: Invited talk
Virtual / UK
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Juliane Manitz | Estimands for Overall Survival in Clinical Trials with Treatment Switching in Oncology | link |
23.03.2022: Royal Statistical Society Manchester local group Graham Dunn Seminar
Contribution of the working group: Invited talk
Virtual / UK
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Kaspar Rufibach | Roche | ICH E9 estimands addendum: Old wine in new bottles or a genuine step forward? | link |
16.12.2021: Royal Statistical Society Session on Design for Medical and Clinical studies
Contribution of the working group: Invited talk
Virtual / UK
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Kaspar Rufibach | Roche | Answering Old Questions with New Tools: Application of the ICH E9 Addendum in Oncology | link |
12.10.2021: ISOQoL 2021
Contribution of the working group: Contributed talk
Virtual /
28.09.2021: DIA webinar – Estimands How and Why - A Real Life Case Study in Oncology
Contribution of the working group: Invited training
Virtual / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Stefan Englert | Bringing estimands to lifelifethrough real case studies through real case studies | link | |
| Paul Bycott | Bringing estimands to lifelifethrough real case studies through real case studies | link | |
| Feng Liu | Bringing estimands to lifelifethrough real case studies through real case studies | link | |
| Jonathan Siegel | Bringing estimands to lifelifethrough real case studies through real case studies | link | |
| Sammi Tang | Bringing estimands to lifelifethrough real case studies through real case studies | link | |
| Jiawei Wei | Bringing estimands to lifelifethrough real case studies through real case studies | link |
21.09.2021: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
Contribution of the working group: Invited talks and panel discussion
Virtual / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Devan Mehrotra | Estimands and Sensitivity Analyses in Clinical Trials - Strengthening Alignment with ICH E9 (R1) | link | |
| Juliane Manitz | Estimands for Overall Survival in Clinical Trials with Treatment Switching in Oncology | link | |
| Yi Liu | Correct and Logical Causal Inference in Randomized Controlled Trials with Biomarker Subgroups | link | |
| Satrajit Roychoudhury | Estimand in Hematologic Oncology Trials | link | |
| Jonathan Siegel | Bayer | Rethinking Censoring and Censoring Mechanisms in Light of the Estimands Framework | link |
24.08.2021: China DIA estimands working group
{-}
Contribution of the working group: Invited talk
Virtual / China
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Kaspar Rufibach | Roche | ICH E9 addendum and principal strati cation | link |
08.08.2021: Joint Statistical Meetings
Contribution of the working group: Topic contributed session
Virtual / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Jianchang Lin | Utilizing Surrogate Endpoints in Adaptive Designs with Delayed Treatment Effect | No presentation available | |
| Steven Sun | Use of estimand Framework in Hematology Oncology Trials: Practical Implementation (no slides available) | No presentation available | |
| Yi Liu | Logic-Respecting Efficacy Measures in the Presence of Prognostic or Predictive Biomarker Subgroups | link | |
| Natalia Kan-Dobrosky | Treatment Switching and estimands for Overall Survival in Oncology Clinical Trials: Issues and Controversies | link |
01.06.2021: PSI EIWG Webinar – Estimands in Oncology - How and Why
Contribution of the working group: Invited training
Virtual / UK
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Stefan Englert | Bringing estimands to lifelifethrough real case studies through real case studies | link | |
| Paul Bycott | Bringing estimands to lifelifethrough real case studies through real case studies | link | |
| Feng Liu | Bringing estimands to lifelifethrough real case studies through real case studies | link | |
| Jonathan Siegel | Bringing estimands to lifelifethrough real case studies through real case studies | link | |
| Sammi Tang | Bringing estimands to lifelifethrough real case studies through real case studies | link | |
| Jiawei Wei | Bringing estimands to lifelifethrough real case studies through real case studies | link |
20.05.2021: Society for Clinical Trials
Contribution of the working group: Topic contributed session
Virtual / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Stefan Englert | How the estimand addendum to the ICH E9 guideline helps structure clinical objectives, guideline helps structure clinical objectives, analyses, and conclusions analyses, and conclusions: A series of oncology case studies | link | |
| Jonathan Siegel | How the estimand addendum to the ICH E9 guideline helps structure clinical objectives, guideline helps structure clinical objectives, analyses, and conclusions analyses, and conclusions: A series of oncology case studies | link | |
| Juliane Manitz | How the estimand addendum to the ICH E9 guideline helps structure clinical objectives, guideline helps structure clinical objectives, analyses, and conclusions analyses, and conclusions: A series of oncology case studies | link | |
| Feng Liu | How the estimand addendum to the ICH E9 guideline helps structure clinical objectives, guideline helps structure clinical objectives, analyses, and conclusions analyses, and conclusions: A series of oncology case studies | link | |
| Steven Sun | How the estimand addendum to the ICH E9 guideline helps structure clinical objectives, guideline helps structure clinical objectives, analyses, and conclusions analyses, and conclusions: A series of oncology case studies | link |
21.04.2021: Duke Industry Statistics Symposium
Contribution of the working group: Invited talk
Virtual / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Natalia Kan-Dobrosky | Estimands in clinical trials with treatment switching | link |
11.02.2021: ASA - FDA - LUNGevity symposium – Statistical considerations in Oncology clinical trials in the COVID-19 era
Contribution of the working group: Symposium
Virtual / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Evgeny Degtyarev & Kaspar Rufibach | Novartis & Roche | How can the estimand framework support decentralized trials? | link |
09.12.2020: Deming Conference on Applied Statistics
Contribution of the working group: Shortcourse
Virtual / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Evgeny Degtyarev & Kaspar Rufibach | Novartis & Roche | Answering Old Questions with New Tools: Application of the ICH E9 Addendum in Oncology | link |
27.11.2020: Working group “Pharmaceutical Industry” of the German Region of the IBS (APF)
Contribution of the working group: Invited talk
Virtual / Germany
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Hannes Buchner & Kaspar Rufibach | Staburo & Roche | Estimands update: Summary of world-wide authority interaction | link |
17.11.2020: The effective statistician podcast
Contribution of the working group: Discussion
Podcast / Germany
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Kaspar Rufibach & Bjoern Bornkamp | Roche & Novartis | A deep dive into principal stratification and causal inference | No presentation available |
05.11.2020: Joint PSI, EFSPI & ASA BIOP Webinar – Estimands
Contribution of the working group: Invited talk
Virtual / UK / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Evgeny Degtyarev | Estimand framework: What are the opportunities in oncology? | link |
22.09.2020: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
Contribution of the working group: Invited talk
Virtual / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Jonathan Siegel | Industry Perspective on Subsequent Therapy: An Estimands Approach | link |
07.09.2020: Webinar of the Basel Biometrics Section – RCTs meeting causal inference – principal stratum strategy and beyond
Contribution of the working group: Invited talk
Webinar / Switzerland
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Kaspar Rufibach | Roche, Basel | Welcome and scene setting | link |
| Vanessa Didelez | Keynote speaker, Leibniz Institute for Prevention Research and Epidemiology, BIPS, Bremen | Time-Varying Treatments in Observational Studies: Lessons for Clinical Trials | link |
| Jack Bowden | University of Exeter | Connecting Instrumental Variable methods for causal inference to the Estimand Framework | link |
| Kelly van Lancker | Ghent University | Efficient, doubly robust estimation of the effect of dose switching for switchers in a randomised clinical trial | link |
| Björn Bornkamp | Novartis, Basel | Principal Stratum Strategy: Potential Role in Drug Development | link |
| Dominik Heinzmann | Roche, Basel | Principal stratum strategy to investigate anti-drug antibody impact on cancer immunotherapy outcome | link |
| Aiesha Zia | Novartis, Basel | Exploring estimation approaches for principal stratum estimands in Phase III randomized trials in CAR-T anti-cancer therapy | link |
| Fabrizia Mealli | University of Florence | The ICH E9 addendum from an academic causal inference perspective and feedback on the previous talks | link |
| Giusi Moffa | University of Basel | Next webinars and closure | link |
| All | Question and Answers | link |
06.09.2020: GMDS & CEN IBS 2020
Contribution of the working group: Contributed talk
Berlin / Germany
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Juliane Manitz | Estimands for Overall Survival in clinical trials with treatment switching | link |
01.08.2020: Joint Statistical Meetings
Contribution of the working group: Topic contributed session
Philadelphia / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Jonathan Siegel | Bayer | Estimand Framework and Its Impact on Drug Development in Oncology | link |
| Anja Schiel (Discussant) | EMA | No presentation available |
29.06.2020: Webinar of the Basel Biometrics Section – Estimands addendum is final – Anything new for oncology?
Contribution of the working group: Invited talk
Webinar / Switzerland
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Kaspar Rufibach | Roche, Basel | Welcome and scene setting | link |
| Anja Schiel | Chair Scientific Advice Working Party, EMA | Experience with the estimand framework in oncology | link |
| Renaud Capdeville | Novartis, Basel | Challenges and open questions in hematology: RATIFY | link |
| Tina Nielsen | Roche, Basel | Challenges and open questions in hematology: GALLIUM | link |
| Hannes Buchner and Ingolf Griebsch | Staburo and Boehringer-Ingelheim | Treatment switching: challenges, estimands, and estimators | link |
| Stefan Englert | Abbvie | Commentary on previous talks taking COVID-19 into account | link |
| All | Question and Answers | link |
11.06.2020: PSI Conference Webinar – Impact of COVID-19 to estimands
Contribution of the working group: Invited talk and panelist
Webinar / UK
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Kaspar Rufibach | Application of the estimand framework to assess the impact of COVID-19 on clinical trials | No presentation available |
21.05.2020: Estimands in Oncology Virtual Panel Discussion (organized by Cytel)
Contribution of the working group: Invited talk and panelist
Virtual / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Kaspar Rufibach | Estimands in oncology | link | |
| Michelle Casey (Discussant) | No presentation available |
06.05.2020: Webinar of the Basel Biometrics Section – Impact of COVID-19 on clinical trials
Contribution of the working group: Invited talk
Virtual / Switzerland
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Evgeny Degtyarev | Short overview on COVID-19 from the Cross-Industry Oncology Estimands Working Group | link |
20.10.2019: ISOQoL
Contribution of the working group: Contributed talk
San Diego / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Rachael Lawrance | Using PROs in clinical trials: what should I know about? | link |
27.09.2019: ESMO
Contribution of the working group: Poster
Barcelona / Spain
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Daniel George | Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC) | link |
24.09.2019: ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
Contribution of the working group: Contributed talks (including FDA discussant)
Washington / USA
23.09.2019: EFSPI Regulatory Statistics Workshop
Contribution of the working group: Invited talk
Basel / Switzerland
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Evgeny Degtyarev | Novartis | Estimand framework: opportunity to rethink some old (and new) problems in Oncology trials? | link |
27.07.2019: Joint Statistical Meetings
Contribution of the working group: Topic contributed session
Denver / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Evgeny Degtyarev | Estimand framework in Oncology drug development impact and opportunities | link | |
| Jonathan Siegel | Importance of censoring mechanisms in selecting appropriate estimands | link | |
| Steven Sun | Sensitivity Analysis vs Supportive Analysis under Estimand Framework: A Case Study in Hematological Malignancies | link | |
| Michelle Casey | Estimand Framework - Are we asking the right questions? A case study in the solid tumor setting | link |
14.07.2019: ISCB conference
Contribution of the working group: Contributed talk
Leuven / Belgium
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Rui Tang | Estimands in the Presence of Treatment Switching | link |
23.06.2019: DIA Annual meeting
Contribution of the working group: Contributed talk
San Diego / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Yi Liu | Estimand Framework and its Impact on Oncology Drug Development: Findings From An Industry Wide Working Group | link |
02.06.2019: PSI annual conference
Contribution of the working group: Contributed talks
London / UK
29.05.2019: Lifetime Data Science Conference
Contribution of the working group: Contributed talks including EMA discussant
Pittsburgh / USA
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Jonathan Siegel | Bayer | Survival Design Strategies in an Estimands Framework | link |
| Shoubhik Mondal | Boehringer-Ingelheim | Traditional sensitivity analyses in oncology clinical trials what questions are they answering? | link |
| Feng Liu | AstraZeneca | Developing Estimands in Oncology Trials: Understand Scientific Questions of Interest | link |
| Anja Schiel (discussant) | EMA | ICH E9(R1) Addendum Blessing or curse? | link |
18.03.2019: DAGStat
Contribution of the working group: Contributed talks
Munich / Germany
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Kaspar Rufibach | Roche | Estimand framework in Oncology drug development – impact and opportunities | link |
| Bjoern Bornkamp | Novartis | Estimation of Principal Stratum Effects, an Overview and Potential Applications in Oncology | link |
| Viktoriya Stalbovskaya | Merus | Estimands in the presence of treatment switching | link |
| Hans-Jochen Weber | Novartis | Implementation of the ICH E9 addendum: RATIFY -A case study in hematology | link |
15.02.2019: HTA EFSPI SIG 1-day event
Contribution of the working group: Invited talk
Berlin / Germany
| Speaker | Institution | Title | Download slides |
|---|---|---|---|
| Evgeny Degtyarev | Novartis | Estimands in Oncology | link |